REVIEW

Research Progress on Interaction between Curcumin and Gut Microbiota

  • CHEN Xinyu , 1 ,
  • PAN Shifeng , 1, 2, * ,
  • XING Hua 1, 2 ,
  • YAN Jie 1
Expand
  • 1 College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China
  • 2 Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China
* associate professor, E-mail:

Received date: 2022-06-23

  Online published: 2023-02-13

Abstract

Curcumin is one of the plant-derived active ingredients that has been deeply studied in recent years, which has extensive pharmacological functions such as anti-inflammatory, antioxidant, antistress, antitumor, antiviral and lowering blood glucose and lipids. At present, numerous studies have demonstrated that curcumin can improve intestinal barriers by regulating the intestinal microbiota. In addition, curcumin can be directly metabolized through the gut microbiota or further generate metabolites with biological activity by the combined metabolism of host and gut microbiota, thereby enhancing the promotion of curcumin on animal intestinal health, indicating that the interaction between curcumin and gut microbiota is of great potential in maintaining the gut health of the host and prevention or treatment of multiple diseases. This paper summarized the latest research progress of the interactions between curcumin and gut microbiota and its application in livestock and poultry production, so as to provide references for the further study of the application of curcumin as a novel feed additive and a potential new antibiotic substitute in livestock and poultry production, which is conducive to promote the healthy development of livestock and poultry breeding.

Cite this article

CHEN Xinyu , PAN Shifeng , XING Hua , YAN Jie . Research Progress on Interaction between Curcumin and Gut Microbiota[J]. Chinese Journal of Animal Nutrition, 2023 , 35(2) : 782 -788 . DOI: 10.12418/CJAN2023.075

肠道微生物是肠道的重要组成部分,也是宿主消化系统正常运转的基础,其数量庞大、种类繁多,且与宿主相互依存、相互影响。肠道微生物不仅与一系列疾病密切相关,还可以通过调节宿主的生理机能来达到抗菌消炎、抗应激、抗癌、抗病毒和免疫调节等多重功效[1]。姜黄素是从姜科姜黄属植物的根茎姜黄中提取的一种多酚类物质,大量研究表明,姜黄素可以通过与肠道微生物相互作用,达到加强宿主机体健康的有益效果[2]。另外,姜黄素因其资源丰富、来源广泛、功能全面、安全性高、毒副作用小、不易使病原菌产生耐药性以及低残留等独特优势而受到广泛关注,并已逐渐显示出在生物医药领域及畜牧兽医领域巨大的应用潜力。

1 肠道微生物

在动物肠道内,有约100万亿个依赖肠道内环境生存的微生物,如细菌、酵母、真菌、原生动物、古菌和病毒等,它们共同构成了肠道微生物群[3]。肠道微生物群并不是恒定不变的,其多样性、相对丰度和代谢产物等与宿主的新陈代谢、营养调控和免疫功能等多个生理过程相关。有研究表明,由于肠道微生物的复杂性及其对宿主健康的重要性,肠道微生物菌群构成了一个巨大而复杂的有机体生态系统,肠道菌群基因的总和可能比人类基因组大100~150倍[4],也被誉为人类的“第二基因组”[5]。在门水平上,肠道微生物群主要分为7个细菌门类:拟杆菌门(Bacteroidetes)、厚壁菌门(Firmicutes)、放线菌门(Actinobacteria)、梭菌门(Fusobacteria)、变形菌门(Proteobacteria)、疣微菌门(Verrucomicrobia)和蓝藻门(Cyanobacteria)[6],其中厚壁菌门和拟杆菌门占肠道菌群的绝大部分,且厚壁菌门/拟杆菌门值也被视为衡量肠道菌群健康与否的一项重要指标。
肠道微生物群在调节肠道运动、消化吸收、防御病原菌、营养物质交换以及免疫调节等过程中均具有重要的作用。肠道微生物可以对不易消化的膳食纤维进行发酵,促进短链脂肪酸(short-chain fatty acid,SCFA)、胆汁酸和维生素等大量活性代谢产物的产生或分泌,从而为宿主提供额外的营养物质,促进肠道健康[7-8]。肠道微生物群不仅直接影响宿主机体的整体健康[9],而且还可以通过分泌抗菌产物、竞争营养、维护肠道屏障的完整性和调节噬菌体的产生等途径抑制病原菌的感染[10]。另有研究表明,肠道微生物群能够通过多种机制改变宿主的能量代谢。例如,遗传肥胖小鼠从饮食中吸收的能量与其肠道中拟杆菌门、厚壁菌门的相对丰度和相对密度呈显著正相关关系[11]。此外,在高脂饮食(high fat diet,HFD)诱导的肥胖小鼠中,肠道微生物群显著减少,且抗肥胖及降血糖分子胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)的表达显著降低[12]

2 姜黄素与肠道微生物间相互作用的研究

2.1 姜黄素

姜黄素是从姜科姜黄属植物的根或茎中提取的一种多酚类物质,在中国和印度传统医药中有着重要的地位[13]。1815年,Vogel和Pelletier首次以不纯形式提取得到姜黄素,然而直到1870年,Daube才提取出纯结晶状态的姜黄素[14]。姜黄素作为一种橙黄色粉末(化学结构见图1),不溶于水和乙醚,易溶于乙醇、二甲基亚砜和丙酮。通常所指的姜黄素是指姜黄素、去甲氧基姜黄素、双去甲氧基姜黄素和环姜黄素等一系列化合物的统称,其中姜黄素是最主要成分,环姜黄素为次要成分。在过去几十年,大量研究数据表明,姜黄素具有抗炎[15-16]、抗氧化应激[17-18]、抗肿瘤[19-20]、抗病毒[21]、降压[22]和降脂[23]等多种药理学功效,能显著抑制炎症反应、神经退行性疾病、心血管疾病、胃肠道疾病以及呼吸系统疾病等[24]
图1 姜黄素的化学结构

Fig.1 Chemical structure of curcumin[14]

2.2 姜黄素对肠道微生物的影响

越来越多的研究表明,肠道菌群的失调与许多代谢性疾病的产生密切相关,而姜黄素处理能显著促进肠道有益菌群的生长,从而对多种代谢性疾病的预防和治疗起到积极作用。Zhai等[25]对赭曲霉毒素诱导的鸭肝病进行研究,结果表明,姜黄素能拮抗赭曲霉毒诱导的肝脏氧化损伤和脂质代谢紊乱;进一步通过肠道菌群16S rRNA基因测序发现,添加姜黄素能明显缓解赭曲霉毒素所导致的丁酸盐产生菌属的减少,并增加肠道菌群的丰度和多样性以及有益菌与有害菌的比例,从而实现姜黄素调节肠道健康的生物学功能。Shen等[26]研究表明,以每天100 mg/kg体重剂量灌胃C57BL/6小鼠姜黄素15 d后,小鼠肠道微生物群组成发生显著改变,其中普雷沃氏菌科(Prevotellaceae)、拟杆菌科(Bacteroidaceae)和理研菌科(Rikenellaceae)等致病菌的丰度显著降低,表明口服姜黄素对肠道菌群组成有显著调节作用。此外,在App/Ps1小鼠[一种阿尔茨海默病(Alzheimer’s disease,AD)模型]上的研究发现,给予姜黄素治疗可显著减轻海马区β淀粉样蛋白的表达,并显著改变肠道中拟杆菌科、普雷沃氏菌科、乳杆菌科(Lactobacillaceae)、理研菌科和普雷沃氏菌属(Prevotella)、拟杆菌属(Bacteroides)、副杆菌属(Parabacteroides)等细菌的丰度[27]。Peterson等[28]进行了一项为期8周的随机、双盲和安慰剂对照试验,探讨姜黄、姜黄素以及安慰剂对30名健康受试者(每组10人)的肠道微生物菌群的影响,研究结果发现,所有受试者肠道微生物菌群的组成均发生显著变化,并出现个体化治疗反应;此外,对比治疗前后每一组的细菌种类数量变化,发现安慰剂组的细菌种类总体减少了15%,而姜黄和姜黄素治疗组的细菌种类分别增加了7%和69%。
在小鼠结肠炎和结肠癌模型上的研究均表明,模型小鼠肠道内普雷沃氏菌科的数量显著高于正常小鼠;而姜黄素给药治疗后,结肠癌小鼠肠道内乳杆菌属(Lactobacillus)数量显著增加,科里杆菌科(Coriobacteriaceae)数量显著减少,提示姜黄素可通过影响肠道菌群的分布显著抑制结肠癌的扩散和转移[29]。一项针对人和动物肠道微生物群与结肠癌关系的研究发现,在结肠癌发病过程中,一些条件性致病菌如另枝菌属(Alistipes)、梭杆菌门(Fusobacteria)、紫单胞菌科(Porphyromonadaceae)、葡萄球菌科(Staphylococcaceae)、科里氏杆菌亚纲(Coriobacteridae)、甲烷杆菌目(Methanobacteriales)和阿克曼氏菌(Akkermansia)的丰度持续增加,而有益菌如乳杆菌属、双歧杆菌属(Bifidobacterium)、瘤胃球菌属(Ruminococcus)、罗氏菌属(Roseburia)、粪杆菌属(Faecalibacterium)和密螺旋体属(Treponema)的丰度则显著减少[30]。综上所述,姜黄素可通过调节肠道微生物菌群的结构调节肠道健康。
Zhang等[31]利用16S rDNA测序技术研究了姜黄素对卵巢切除大鼠肠道菌群的影响,结果表明,卵巢切除引起的雌激素缺乏可引起大鼠肠道菌群结构和丰度改变,而补充姜黄素可部分逆转雌激素缺乏所导致的肠道菌群多样性的减少;在属水平上,与假手术组大鼠相比,切除卵巢组大鼠肠道中Incertae_SedisAnaerovorax、幽门螺旋杆菌属(Helicobacteria)、厌氧棍状菌属(Anaerotruncus)的数量以及沙雷氏菌属(Serratia)、希瓦氏菌属(Shewanella)、假单胞菌属(Pseudomonas)、微小杆菌属(Exiguobacterium)的数量显著下降,肠道菌群多样性显著降低;而与切除卵巢组大鼠相比,给予姜黄素治疗的卵巢切除大鼠肠道中肠道菌群多样性显著增加,尤其是PapillibacterHelicobacteria的数量显著增多,表明姜黄素能够部分逆转卵巢切除后雌激素缺乏引起的肠道细菌多样性的减少,从而有助于防治卵巢切除后的增重。
Feng等[32]研究表明,饲粮中添加姜黄素可以显著逆转HFD诱导的大鼠肠道菌群结构失衡,改善肠道屏障的通透性,缓解HFD诱导的肝脏脂肪变性、代谢性内毒素血症和肠道炎症。在门水平上,姜黄素处理能够显著降低肠道菌群中螺旋菌门(Spirochaetae)、软壁菌门(Tenericutes)和迷踪菌门(Elusimicrobia)的丰度,并显著提高放线菌门的丰度;在属水平上,肠道微生物菌群中柯林斯氏菌属(Collinsella)、链球菌属(Streptococcus)、萨特氏菌属(Sutterella)、孪生球菌属(Gemella)、海旋菌属(Thalassospira)、戈登氏杆菌属(Gordonibacter)、放线菌属(Actinomyces)等丰度显著增加,而密螺旋体属、奎因氏菌属(Quinella)、拟普雷沃氏菌属(Alloprevotella)、瘤胃球菌属、另枝菌属、Elusimicrobium、厌氧细杆菌属(Anaerofilum)、Papillibacter等丰度显著降低[32]。另有一项研究表明,姜黄素处理能够显著降低肠道微生物菌群中变形菌门的丰度和厚壁菌门与拟杆菌门的比例,并显著提升肠道微生物菌群中阿克曼氏菌的丰度,从而改善低剂量双酚A诱导的小鼠肝脏脂肪变性[33]。以上研究均表明,姜黄素可能通过降低肠道内有害菌群的数量或增加有益菌的丰度,促进致病菌群向有益菌群的转变,实现其对肠道健康的保护作用。

2.3 姜黄素和肠道微生物间的相互作用

姜黄素不仅可以通过调节宿主肠道微生物群的结构丰度水平实现其广泛的生物学功能,还会被宿主肠道内的微生物群代谢分解,产生多种活性代谢产物,从而参与宿主体内多种生理过程的调控[34]。应用体外试验,探讨人类粪便微生物对姜黄素的代谢情况时发现,在体外发酵24 h后,高达24%的姜黄素、61%的去甲氧基姜黄素(demethoxycurcumin,DMC)和87%的双去甲氧基姜黄素(Bis-DMC)被人类粪便微生物群降解[35]。在发酵过程中检测到3种主要代谢物,即四氢姜黄素(tetrahydrocurcumin,THC)、二氢阿魏酸(dihydroferulic acid,DFA)和1种相对分子质量为181.087 34的代谢物,初步鉴定为1-(4-羟基-3-甲氧苯基)-2-丙醇[1-(4-hydroxy-3-methoxyphenyl)-2-propanol][35]。此外有研究者提出,姜黄素的分解产物也会进一步影响宿主肠道菌群的组成及丰度。例如,四氢姜黄素可通过降低小鼠肠道微生物群中变形菌门、放线菌门的相对丰度以及厚壁菌门与拟杆菌门的比例,使GLP-1的表达和胰岛素分泌增加,血糖含量显著降低,从而保护宿主胰岛细胞免受高血糖损伤,并改善肠道微生物群的失调[36]。在小鼠模型试验中,将饲喂四氢姜黄素的供体小鼠的粪便微生物群移植于卵白蛋白诱导的哮喘小鼠受体,可显著降低哮喘小鼠肠道微生物群中厚壁菌门与拟杆菌门的比例,同时还降低了促炎肠道菌群例如变形菌门、Intestinimonas、未鉴定瘤胃球菌科(unidentified_Ruminococcaceae)和毛螺菌科(Lachnospiraceae)的相对丰度;并且,经四氢姜黄素治疗的哮喘小鼠表现出比姜黄素治疗更好的预防作用,其肠道菌群中未鉴定瘤胃球菌科、RomboutsiaIntestinimonas、阿克曼氏菌和Mucispirillum的相对丰度与辅助性T淋巴细胞2(T helper lymphocyte 2,Th2)相关因子水平呈显著正相关,从而显著改善肺部和结肠组织的症状和Th2介导的炎症[37]。以上结果表明,肠道微生物对姜黄素的降解产物,增加了姜黄素的生物作用,促进了其生物学功能的发挥。
Lou等[38]进一步探讨了人肠道菌群对姜黄素的分解作用,发现有23种新的代谢产物产生,并且揭示了肠道菌群主要通过还原、去甲基化、乙酰化和羟基化等几种途径对姜黄素进行分解代谢,产生去甲氧基姜黄素和双去甲氧基姜黄素等混合物。有研究表明,去甲氧基姜黄素可以通过抑制诱导型一氧化氮合酶(inducible nitric oxide synthase,iNOS)的表达及减少一氧化氮(NO)的分泌,抑制炎症反应[39]。还有研究发现,在饲粮中添加双去甲氧基姜黄素能够显著提高肉鸡肠道粪杆菌属的相对丰度,降低拟杆菌属和Subdoligranulum的相对丰度,同时还可以显著改善肠道黏膜形态、维持肠道屏障完整性、抑制促炎因子的分泌以及促进肠道微生物群失调的恢复,从而缓解脂多糖(lipopolysaccharide,LPS)诱导的肉鸡肠道炎症损伤[40]。Zhang等[41]研究表明,在肉鸡饲粮中添加双去甲氧基姜黄素可以增加空肠中谷胱甘肽(glutathione,GSH)的含量以及超氧化物歧化酶(superoxide dismutase,SOD)和谷胱甘肽还原酶(glutathione reductase,GR)的活性,并提高回肠GSH的含量及SOD和谷胱甘肽S-转移酶(glutathione S-transferase,GST)的活性,同时显著降低空肠、回肠组织中氧化还原电位和空肠氧化型谷胱甘肽(oxidized glutathione,GSSG)的含量。这说明去甲氧基姜黄素和双去甲氧基姜黄素具有良好的抗氧化和抗炎作用,可以作为一种新型饲料添加剂广泛应用于畜禽养殖中。此外,从小鼠粪便中分离的巨大芽孢杆菌DCMB-002菌株能够通过还原、羟基化、去甲基化和去甲氧基化等作用将姜黄素进行分解,根据示踪高效液相色谱结合四极杆飞行时间串联质谱分析,一共鉴定出7种加氢转化代谢物,其中6种是首次报告[42],表明巨大芽孢杆菌具备将姜黄素转化为各种衍生物的能力[42]
姜黄素被肠道微生物代谢是分阶段进行的,在第1阶段,形成3种主要代谢产物,即六氢姜黄素(约占42%)、四氢姜黄素(约占50%)(化学结构见图2[43-44])以及八氢姜黄素[45];第2阶段,姜黄素及其第1阶段代谢产物都具有酚羟基和醇羟基的结构,极易与葡萄糖醛酸酯和O-硫酸酯结合,得到相应的化合物[38,46],其中以六氢姜黄素的葡萄糖醛酸化为血浆、组织或细胞中最主要的第2阶段代谢产物[47]。Holder等[48]通过验证也发现,姜黄素的最终代谢产物中95%都是以葡萄糖醛酸化的形式存在。姜黄素作为一种亲脂性多酚,其系统生物利用度较差,容易被人体肠道菌群生物转化,产生不同的代谢物。在人上的研究结果表明,人类粪便中分离出的大肠杆菌能够将姜黄素转化为四氢姜黄素、二氢姜黄素[49]
图2 姜黄素主要代谢产物的化学结构

Fig.2 Chemical structure of main metabolites of curcumin[43-44]

姜黄素可调节肠道菌群,也可进一步由宿主肠道菌群代谢产生生物活性物质,在肠道中发挥重要作用,显示出这些代谢产物在预防和治疗多种疾病方面具有巨大的应用潜力。同时,个体间肠道微生物群的组成差异将导致肠道内姜黄素的生物转化效率不同,因此,姜黄素对宿主有机体生理功能的调节作用,还取决于个体肠道中的微生物种群类型。

3 小结

综上所述,肠道微生物对宿主动物肠道健康及机体的整体健康都具有积极的保护作用,有助于改善肠道微生物平衡、新陈代谢和肠道完整性。姜黄素可通过调节肠道微生物的组成及丰度,或与肠道菌群之间产生相互作用,共同参与对动物机体多种生物学过程的调控。然而,姜黄素吸收率低、生物利用率不高、毒性强等弊端极大地限制了其药用潜力和临床应用。因此,未来一方面需要进一步挖掘提高姜黄素生物利用率的可靠方法(如制备胶束、脂质体、磷脂复合物、微乳液、纳米结构脂质载体和生物聚合物纳米颗粒等),另一方面还需要深入探讨姜黄素潜在的生物学功能,尤其是与肠道菌群之间的相互作用在维持机体健康及疾病治疗中的潜在效果,从而促进其在养殖领域的广泛应用。此外,还需要进一步研究肠道菌群潜在的代谢机制以及姜黄素经肠道菌群转化后生成的姜黄素代谢产物对肠道菌群组成的影响,从而促进姜黄素在生物医药及畜牧兽医生产中的应用。
[1]
BLANDER J M, LONGMAN R S, ILIEV I D, et al. Regulation of inflammation by microbiota interactions with the host[J]. Nature Immunology, 2017, 18(8):851-860.

DOI PMID

[2]
PLUTA R, JANUSZEWSKI S, UŁAMEK-KOZIOŁ M. Mutual two-way interactions of curcumin and gut microbiota[J]. International Journal of Molecular Sciences, 2020, 21(3):1055.

DOI

[3]
BELIZÁRIO J E, FAINTUCH J. Microbiome and gut dysbiosis[M]. Cham: Springer International Publishing, 2018:459-476.

[4]
LOZUPONE C A, STOMBAUGH J I, GORDON J I, et al. Diversity,stability and resilience of the human gut microbiota[J]. Nature, 2012, 489(7415):220-230.

DOI

[5]
GRICE E A, SEGRE J A. The human microbiome:our second genome[J]. Annual Review of Genomics and Human Genetics, 2012, 13:151-170.

DOI

[6]
BÄCKHED F, LEY R E, SONNENBURG J L, et al. Host-bacterial mutualism in the human intestine[J]. Science, 2005, 307(5717):1915-1920.

DOI PMID

[7]
HEIMANN E, NYMAN M, DEGERMAN E. Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes[J]. Adipocyte, 2015, 4(2):81-88.

DOI PMID

[8]
MAKKI K, DEEHAN E C, WALTER J, et al. The impact of dietary fiber on gut microbiota in host health and disease[J]. Cell Host & Microbe, 2018, 23(6):705-715.

[9]
JANDHYALA S M, TALUKDAR R, SUBRAMANYAM C, et al. Role of the normal gut microbiota[J]. World Journal of Gastroenterology, 2015, 21(29):8787-8803.

DOI PMID

[10]
DUCARMON Q R, ZWITTINK R D, HORNUNG B V H, et al. Gut microbiota and colonization resistance against bacterial enteric infection[J]. Microbiology and Molecular Biology Reviews, 2019, 83(3):e00007-e00019.

[11]
TURNBAUGH P J, LEY R E, MAHOWALD M A, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature, 2006, 444(7122):1027-1031.

DOI

[12]
EVERARD A, CANI P D. Gut microbiota and GLP-1[J]. Reviews in Endocrine and Metabolic Disorders, 2014, 15(3):189-196.

DOI PMID

[13]
UNLU A, NAYIR E, DOGUKAN KALENDEROGLU M, et al. Curcumin (turmeric) and cancer[J]. Journal of B.U.ON.:Official Journal of the Balkan Union of Oncology, 2016, 21(5):1050-1060.

[14]
SHISHODIA S H, SETHI G A, AGGARWAL B B. Curcumin:getting back to the roots[J]. Annals of the New York Academy of Sciences, 2005, 1056(1):206-217.

DOI

[15]
ISLAM T, KOBOZIEV I, ALBRACHT-SCHULTE K, et al. Curcumin reduces adipose tissue inflammation and alters gut microbiota in diet-induced obese male mice[J]. Molecular Nutrition & Food Research, 2021, 65(22):e2100274.

[16]
FERGUSON J J A, ABBOTT K A, GARG M L. Anti-inflammatory effects of oral supplementation with curcumin:a systematic review and meta-analysis of randomized controlled trials[J]. Nutrition Reviews, 2021, 79(9):1043-1066.

DOI

[17]
PARK J H, LEE B M, KIM H S. Potential protective roles of curcumin against cadmium-induced toxicity and oxidative stress[J]. Journal of Toxicology and Environmental Health Part B, 2021, 24(3):95-118.

DOI

[18]
ALIZADEH N, MALAKZADEH S. Antioxidant, antibacterial and anti-cancer activities of β-and γ-CDs/curcumin loaded in chitosan nanoparticles[J]. International Journal of Biological Macromolecules, 2020, 147:778-791.

DOI PMID

[19]
TERMINI D, DEN HARTOGH D J, JAGLANIAN A, et al. Curcumin against prostate cancer:current evidence[J]. Biomolecules, 2020, 10(11):1536.

DOI

[20]
GARUFI A, BALDARI S, PETTINARI R, et al. A ruthenium (Ⅱ)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status[J]. Journal of Experimental & Clinical Cancer Research, 2020, 39(1):122.

[21]
ARDEBILI A, POURIAYEVALI M H, ALESHIKH S, et al. Antiviral therapeutic potential of curcumin:an update[J]. Molecules (Basel,Switzerland), 2021, 26(22):6994.

DOI

[22]
CZYZYNSKA-CICHON I, JANIK-HAZUKA M, SZAFRANIEC-SZCZESNY J, et al. Low dose curcumin administered in hyaluronic acid-based nanocapsules induces hypotensive effect in hypertensive rats[J]. International Journal of Nanomedicine, 2021, 16:1377-1390.

DOI

[23]
XIE Z L, SHEN G Z, WANG Y, et al. Curcumin supplementation regulates lipid metabolism in broiler chickens[J]. Poultry Science, 2019, 98(1):422-429.

DOI PMID

[24]
HASANZADEH S, READ M I, BLAND A R, et al. Curcumin:an inflammasome silencer[J]. Pharmacological Research, 2020, 159:104921.

DOI

[25]
ZHAI S S, RUAN D, ZHU Y W, et al. Protective effect of curcumin on ochratoxin A-induced liver oxidative injury in duck is mediated by modulating lipid metabolism and the intestinal microbiota[J]. Poultry Science, 2020, 99(2):1124-1134.

DOI PMID

[26]
SHEN L, LIU L, JI H F. Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications[J]. Food & Nutrition Research, 2017, 61(1):1361780.

[27]
SUN Z Z, LI X Y, WANG S, et al. Bidirectional interactions between curcumin and gut microbiota in transgenic mice with Alzheimer's disease[J]. Applied Microbiology and Biotechnology, 2020, 104(8):3507-3515.

DOI

[28]
PETERSON C T, VAUGHN A R, SHARMA V, et al. Effects of turmeric and curcumin dietary supplementation on human gut microbiota:a double-blind,randomized,placebo-controlled pilot study[J]. Journal of Evidence-Based Integrative Medicine, 2018, 23:2515690X18790725.

[29]
MCFADDEN R M T, LARMONIER C B, SHEHAB K W, et al. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention[J]. Inflammatory Bowel Diseases, 2015, 21(11):2483-2494.

DOI

[30]
BORGES-CANHA M, PORTELA-CIDADE J P, DINIS-RIBEIRO M, et al. Role of colonic microbiota in colorectal carcinogenesis:a systematic review[J]. Revista Espanola de Enfermedades Digestivas, 2015, 107(11):659-671.

[31]
ZHANG Z G, CHEN Y J, XIANG L H, et al. Effect of curcumin on the diversity of gut microbiota in ovariectomized rats[J]. Nutrients, 2017, 9(10):1146.

DOI

[32]
FENG W H, WANG H D, ZHANG P Z, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats[J]. Biochimica et Biophysica Acta (BBA):General Subjects, 2017, 1861(7):1801-1812.

DOI

[33]
HONG T, JIANG X, ZOU J, et al. Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice[J]. The Journal of Nutritional Biochemistry, 2022, 109:109103.

DOI

[34]
TSUDA T. Curcumin as a functional food-derived factor: degradation products,metabolites,bioactivity,and future perspectives[J]. Food & Function, 2018, 9(2):705-714.

[35]
TAN S, CALANI L, BRESCIANI L, et al. The degradation of curcuminoids in a human faecal fermentation model[J]. International Journal of Food Sciences and Nutrition, 2015, 66(7):790-796.

DOI PMID

[36]
YUAN T M, YIN Z J, YAN Z X, et al. Tetrahydrocurcumin ameliorates diabetes profiles of db/db mice by altering the composition of gut microbiota and up-regulating the expression of GLP-1 in the pancreas[J]. Fitoterapia, 2020, 146:104665.

DOI

[37]
WU Y F, CHEN Y Q, LI Q, et al. Tetrahydrocurcumin alleviates allergic airway inflammation in asthmatic mice by modulating the gut microbiota[J]. Food & Function, 2021, 12(15):6830-6840.

[38]
LOU Y, ZHENG J Q, HU H H, et al. Application of ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry to identify curcumin metabolites produced by human intestinal bacteria[J]. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 2015, 985:38-47.

DOI

[39]
SOMCHIT M, CHANGTAM C, KIMSENG R, et al. Demethoxycurcumin from Curcuma longa rhizome suppresses iNOS induction in an in vitro inflamed human intestinal mucosa model[J]. Asian Pacific Journal of Cancer Prevention, 2014, 15(4):1807-1810.

DOI

[40]
ZHANG J F, YANG Y X, HAN H L, et al. Bisdemethoxycurcumin attenuates lipopolysaccharide-induced intestinal damage through improving barrier integrity,suppressing inflammation,and modulating gut microbiota in broilers[J]. Journal of Animal Science, 2021, 99(11):skab296.

[41]
ZHANG J F, HAN H L, ZHANG L L, et al. Dietary bisdemethoxycurcumin supplementation attenuates lipopolysaccharide-induced damages on intestinal redox potential and redox status of broilers[J]. Poultry Science, 2021, 100(5):101061.

DOI

[42]
AN C Y, SUN Z Z, SHEN L, et al. Biotransformation of food spice curcumin by gut bacterium Bacillus megaterium DCMB-002 and its pharmacological implications[J]. Food & Nutrition Research, 2017, 61(1):1412814.

[43]
LESTARI M L A D, INDRAYANTO G. Curcumin[J]. Profiles of Drug Substances,Excipients and Related Methodology, 2014, 39:113-204.

[44]
XIE Q F, CHENG J J, CHEN J F, et al. Comparation of anti-inflammatory and antioxidantactivities of curcumin,tetrahydrocurcuminand octahydrocurcuminin LPS-stimulated RAW264.7 macrophages[J]. Evidence-Based Complementary and Alternative Medicine:eCAM, 2020, 2020:8856135.

[45]
LI Z Z, SUN Y, SONG M Y, et al. Gut microbiota dictate metabolic fate of curcumin in the colon[J]. The FASEB Journal, 2017, 31(S1):646.12.

[46]
ASAI A, MIYAZAWA T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma[J]. Life Sciences, 2000, 67(23):2785-2793.

DOI PMID

[47]
METZLER M, PFEIFFER E, SCHULZ S I, et al. Curcumin uptake and metabolism[J]. BioFactors, 2013, 39(1):14-20.

DOI PMID

[48]
HOLDER G M, PLUMMER J L, RYAN A J. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat[J]. Xenobiotica;the Fate of Foreign Compounds in Biological Systems, 1978, 8(12):761-768.

DOI

[49]
HASSANINASAB A, HASHIMOTO Y, TOMITA-YOKOTANI K, et al. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism[J]. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(16):6615-6620.

DOI PMID

Outlines

/